Antiplatelet and anticoagulant drugs in interventional radiology

CardioVascular and Interventional Radiology

Volumn 35, Issue 1, 2012, Pages 30-42

  Altenburg, Alexander ^a   Haage, Patrick ^a  

^a HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Anticoagulation; Antiplatelet therapy; Drugs; Interventional angiography

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN IIIA RECEPTOR ANTAGONIST; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PRASUGREL; PROTAMINE; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; AGRANULOCYTOSIS; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ANGIONEUROTIC EDEMA; ANTICOAGULATION; APLASTIC ANEMIA; ASTHMA; BACKACHE; BLEEDING; BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; DYSPEPSIA; EDEMA; EROSION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HYPOTENSION; INTERVENTIONAL RADIOLOGY; INTESTINE ULCER; KIDNEY FUNCTION; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; NAUSEA AND VOMITING; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PETECHIA; PRIORITY JOURNAL; PRURITUS; RECEPTOR BLOCKING; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH HEMORRHAGE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; URTICARIA; VOMITING;

ANTICOAGULANTS; DRUG RESISTANCE; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RADIOGRAPHY, INTERVENTIONAL;

EID: 84857044210     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-011-0204-0     Document Type: Review

References (63)

1. InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II) 2007 Eur J Vasc Endovasc Surg 33 Suppl 1 S63
2. JT Brandt CD Payne SD Wiviott G Weerakkody, et al. 2007 A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 1 e9 e16 17174640 10.1016/j.ahj.2006.10.010 (Pubitemid 44895531)
3. SD Wiviott D Trenk AL Frelinger M O'Donoghue, et al. 2007 Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planed percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolyses in Myocardial Infarction 44 trial Circulation 116 25 2923 2932 18056526 10.1161/CIRCULATIONAHA.107.740324 1:CAS:528:DC%2BD2sXhsVWjsr7N (Pubitemid 350291199)
4. SD Wiviott E Braunwald CH McCabe G Montalescot, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2001 2015 17982182 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN (Pubitemid 350106708)
5. DJ Angiolillo JF Saucedo R Deraad, et al. 2010 Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 13 1017 1023 20846599 10.1016/j.jacc.2010.02.072 1:CAS:528:DC%2BC3cXhtlejs7zI
6. L Wallentin RC Becker A Dudaj, et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045 1057 19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
7. Lammer J (2007) Clinical practice in interventional radiology - from the CIRSE task force on clinical practice in IR, vol. I:63
8. Antiplatelet Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, MI, and stroke in high-risk patients Br Med J 324 71 86 10.1136/bmj.324.7329.71
9. J Vane 1971 Inhibition of prostaglandin biosynthesis as a mechanism of action of ASA-like drugs Nature 231 232 235 1:CAS:528:DyaE3MXltVyjur4%3D
10. JB Smith AL Willis 1971 Aspirin selectively inhibits prostaglandin production in human platelets Nature 231 235 237 1:CAS:528:DyaE3MXkvFOhsr0%3D
11. GJ Roth PW Majerus 1975 The mechanism of the effect of ASA on human platelets. Acetylation of a particular fraction protein J Clin Invest 56 624 632 1159076 10.1172/JCI108132 1:CAS:528:DyaE2MXlslarsr4%3D
12. K Schror 1997 Aspirin and platelets: the antiplatelet actions of ASA and its role in thrombosis treatment and prophylaxis Semin Thromb Hemost 23 349 355 9263351 10.1055/s-2007-996108 1:STN:280:DyaK2svgvVygsA%3D%3D
13. Becker RC, Spencer FA (2006) Fibrinolytic and antithrombotic therapy. Oxford University Press, Oxford, UK
14. JR O'Brien 1968 Effects of salicylates on human platelets Lancet 1 779 783 4171129 10.1016/S0140-6736(68)92228-9
15. E Smecuol M Sanchez A Suarez, et al. 2009 Low-dose ASA affects the small bowel mucosa: results of a pilot study with a multidimensional assessment Clin Gastroenterol Hepatol 7 524 529 19249402 10.1016/j.cgh.2008.12.019 1:CAS:528:DC%2BD1MXptVejsrs%3D
16. O Schaefer J Gore 1999 Aspirin sensitivity: the role for ASA challenge and desensitization in post MI patients Cardiology 91 8 13 10393393 10.1159/000006871 1:CAS:528:DyaK1MXkslegt70%3D (Pubitemid 29278426)
17. S Silberman C Neukirch-Stop PG Steg 2005 Rapid desensitization procedure for patients with ASA hypersensity undergoing coronary stenting Am J Cardiol 95 509 510 15695141 10.1016/j.amjcard.2004.10.022 1:CAS:528:DC%2BD2MXptlCksw%3D%3D (Pubitemid 40247551)
18. EH Awtry J Loscalzo 2000 Aspirin Circulation 101 1206 1218 10715270 1:CAS:528:DC%2BD3cXit1aksL0%3D (Pubitemid 30146625)
19. RJ Peters SR Mehzta KA Fox, et al. 2003 Effects of ASA dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: oberservations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 1682 1687 14504182 10.1161/01.CIR.0000091201.39590.CB 1:CAS:528:DC%2BD3sXns1Cgu78%3D (Pubitemid 37243654)
20. PM Mannucci ZM Ruggeri FI Pareti A Capitanio 1977 A new pharmacological approach to the management of haemophilia and von Willebrand disease Lancet 1 869 872 67283 10.1016/S0140-6736(77)91197-7 1:STN:280:DyaE2s7mvFOrsg%3D%3D (Pubitemid 8079684)
21. GJ Hankey JW Eikelboom 2004 Aspirin resistance Br Med J 328 477 479 10.1136/bmj.328.7438.477 (Pubitemid 38293602)
22. FM Gengo L Rubin M Robson M Rainka, et al. 2008 Effects of ibuprofen on the magnitude and duration of ASA's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis J Clin Pharmacol 48 1 117 122 18094224 10.1177/0091270007310379 1:CAS:528:DC%2BD1cXhtVGqtb0%3D (Pubitemid 350292265)
23. MP Schuijt HW Huntjens-Fleuren M de Metz EJ Vollaard 2009 The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers Br J Pharmacol 157 6 931 934 19466986 10.1111/j.1476-5381.2009.00243.x 1:CAS:528: DC%2BD1MXhtVChu7nL
24. FM Gengo M Rainka M Robson MF Gengo A Forrest M Hourihane, et al. 2008 Prevalence of platelet nonresponsiveness to ASA in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events J Clin Pharmacol 48 335 343 18223144 10.1177/0091270007313324 1:CAS:528: DC%2BD1cXjs1ektL4%3D (Pubitemid 351257777)
25. JD Snoep MMC Hovens JCJ Eikenboom JG van der Bom MV Huisman 2007 Association of laboratory-defined ASA resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 1593 1599 17698681 10.1001/archinte.167.15.1593 (Pubitemid 47280339)
26. AL Frelinger MI Furman MD Linden, et al. 2006 Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independend pathway: a 700-patient study of ASA resistance Circulation 27 2888 2896 10.1161/CIRCULATIONAHA.105.596627 (Pubitemid 44297229)
27. CAPRIE Steering Committee 1996 A randomised, blinded trial of clopidogrel versus ASA in patients at risk for ischemic events (CAPRIE) Lancet 348 1329 1339 10.1016/S0140-6736(96)09457-3 (Pubitemid 26383772)
28. DL Bahatt DP Chew AT Hirsch, et al. 2001 Superiority of clopidogrel versus ASA in patients with prior cardiac surgery Circulation 103 363 368 (Pubitemid 32105974)
29. C Gachet P Savi P Ohlmann, et al. 1992 ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes - an effect selectively blocked by the thienopyridin clopidogrel Thromb Haemost 68 79 83 1514178 1:CAS:528:DyaK38Xlt1Chtb4%3D
30. G Hollopter HM Jantzen D Cincent, et al. 2001 Identification of the platelet ADP receptor targeted by antithombotic drugs Nature 409 202 207 10.1038/35051599 (Pubitemid 32144286)
31. H Caplain F Donat C Gaud J Necciari 1999 Pharmacokinetics of clopidogrel Semin Thromb Hemost 25 Suppl 2 25 28 10440419 1:CAS:528:DyaK1MXltVKmurY%3D (Pubitemid 29350288)
32. JD Easton 1999 Clinical aspects of the use of clopidogrel, a new antiplatelet agent Semin Thromb Hemost. 25 Suppl 2 77 82 10440429 1:CAS:528:DyaK1MXltVKmu7Y%3D (Pubitemid 29350298)
33. PA Gurbel KP Bliden KM Hayes, et al. 2005 The relation of dosing to clopidogrel responsiveness and the incidence of high posttreatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 45 9 1392 1396 15862408 10.1016/j.jacc.2005.01.030 1:CAS:528:DC%2BD2MXjvVKku70%3D (Pubitemid 40615608)
34. M Lotrionte GG Biondi-Zoccai P Agostoni, et al. 2007 Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Am J Cardiol 100 8 1199 1206 17920357 10.1016/j.amjcard.2007.05. 048 1:CAS:528:DC%2BD2sXhtFCjsLfN (Pubitemid 47520598)
35. D Sibbing S Braun T Morath, et al. 2009 Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 849 856 19264241 10.1016/j.jacc.2008.11.030 1:CAS:528:DC%2BD1MXlslagsrk%3D
36. B Leithäuser D Zielske UT Seyfert F Jung 2008 Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel Clin Hemorheol Microcirc 39 1386 1391
37. A Schornig FJ Neumann A Kastrati, et al. 1996 A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med 334 1084 1089 10.1056/NEJM199604253341702 (Pubitemid 26120185)
38. P Urban C Macaya H-J Rupprecht for the MATTIS Investigators, et al. 1998 Randomized evaluation of anticoagulant versus antiplatelet therapy after coronary stent implantation in high-risk patients. The multicenter ASA and ticlopidine trial after coronary stenting (MATTIS) Circulation 98 2126 2132 9815866 1:CAS:528:DyaK1cXnvFaqsro%3D (Pubitemid 28527471)
39. S Yusuf F Zhao SR Mehta, et al. 2001 Effects of clopidogrel in addition to ASA in patients with acute coronary syndromes without ST-segment increase N Engl J Med 345 494 502 11519503 10.1056/NEJMoa010746 1:CAS:528: DC%2BD3MXms1arsrY%3D (Pubitemid 32758501)
40. S Silber P Albertsson F Avilés, et al. 2005 Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 26 804 847 15769784 10.1093/eurheartj/ehi564
41. SC Smith Jr TE Feldman JW Hirshfeld, et al. 2006 ACC/AHA Task Force on Practice Guidelines; ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 156 175 16391169 10.1161/CIRCULATIONAHA. 105.170815 (Pubitemid 43958502)
42. FM McKevitt MS Randall TJ Cleveland, et al. 2005 The benefits of combined antiplatelet treatment in carotid artery stenting Eur J Vasc Endovasc Surg 29 522 527 15966092 10.1016/j.ejvs.2005.01.012 1:STN:280:DC%2BD2MzhsVOhtA%3D%3D (Pubitemid 40973849)
43. Clinical Practice in Interventional Radiology (2007) From the CIRSE Task Force on Clinical Practice in IR. Volume I:681
44. J-H Buhk A Wellmer M Knauth 2006 Late in-stent thrombosis following carotid angioplasty and stenting Neurology 66 1594 1596 16717230 10.1212/01.wnl.0000216141.01262.77 (Pubitemid 43958567)
45. PP Cacoub DL Bhatt PG Steg, et al. 2009 Patients with peripheral arterial disease in the CHARISMA trial Eur Heart J 30 131 132
46. MHU Usman LA Notaro R Nagarakanti, et al. 2009 Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 103 1107 1112 19361598 10.1016/j.amjcard.2009.01.003 1:CAS:528:DC%2BD1MXktl2jsbk%3D
47. PA Horwitz JA Berlin WH Sauer WK Laskey RJ Krone SE Kimmel Registry Committee of the Society for Cardiac Angiography Interventions 2003 Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry) Am J Cardiol 91 803 806 12667564 10.1016/S0002-9149(03)00012-2 1:CAS:528:DC%2BD3sXit12gsrY%3D (Pubitemid 36363725)
48. RA Reiter F Mayr H Blazicek E Galehr 2003 Demopressin antagonizes the in vitro platelet dysfunction induced by GP IIb/IIIa inhibitors and ASA Blood 102 4594 4599 12920042 10.1182/blood-2002-11-3566 1:CAS:528:DC%2BD3sXpslGrt78%3D (Pubitemid 37494129)
49. G Tepe J Wiskirchen P Pereira, et al. 2008 GP IIb/IIIa blockade during peripheral artery interventions CVIR 31 1 8 13 17479207 10.1007/s00270-005-0266- y
50. DF Kong V Hasselblad RA Harrington, et al. 2003 Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions Am J Cardiol 92 651 655 12972100 10.1016/S0002-9149(03)00816-6 1:CAS:528:DC%2BD3sXntVChsb0%3D (Pubitemid 37103012)
51. NW Shammas EJ Dippel GA Shammas, et al. 2008 Utilization of GP IIb/IIIa inhibitors in peripheral percutanous interventions: current applications and in-hospital outcomes at a tertiary referral center J Invasive Cardiol 20 6 266 269 18523317 (Pubitemid 351919766)
52. K Ouriel F Castaneda T McNamara, et al. 2004 Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial J Vasc Intervent Radiol 15 3 229 238 10.1097/01.RVI.0000116193.44877.0F (Pubitemid 38316444)
53. KJ Rocha-Singh J Rutherford 2005 Glycoprotein IIb/IIIa inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial Catheter Cardiovasc Interv 66 470 473 16284982 10.1002/ccd.20573 (Pubitemid 41779009)
54. AB McIff 2005 Worksheets for use while performing carotid stenting or stroke intervention Tech Vasc Interv Radiol 8 3 129 130 16376788 10.1053/j.tvir.2005.10.004
55. S Beguin T Lindhout HC Hemker 1988 The mode of action of heparin in plasma Thromb Haemost 60 457 462 3238649 1:CAS:528:DyaL1MXht1ygtr4%3D (Pubitemid 19023741)
56. DP Chew DL Bhatt AM Lincoff, et al. 2001 Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials Circulation 103 961 966 11181470 1:STN:280:DC%2BD3M3msFajsw%3D%3D (Pubitemid 32183801)
57. L Rauova M Poncz S McKenzie MP Reilly G Arepally JW Weisel 2005 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia Blood 105 131 138 15304392 10.1182/blood-2004- 04-1544 1:CAS:528:DC%2BD2MXis1GrsQ%3D%3D (Pubitemid 40053074)
58. BH Chong 2003 Heparin-induced thrombocytopenia J Thromb Haemost 1 1471 1478 12871282 10.1046/j.1538-7836.2003.00270.x 1:CAS:528:DC%2BD2cXktFOjsbo%3D
59. MM Samam GT Gerotziafas 2003 Evaluation of the pharmacological properties and clinical results of the systhetic pentasaccharide fondaparinux Thromb Res 109 1 11 10.1016/S0049-3848(03)00030-6 (Pubitemid 36385042)
60. CN Berry C Girardot C Lecoffre C Lunven 1994 Effects of the synthetic thrombin inhibitor argatraban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin Thromb Haemost 72 381 386 7855788 1:CAS:528:DyaK2MXis1eqsLk%3D (Pubitemid 24280776)
61. SH Duda M Bosiers J Lammer, et al. 2005 Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease. The SIROCCO II trial J Vasc Interv Radiol 16 3 331 338 15758128 10.1097/01.RVI.0000151260. 74519.CA (Pubitemid 40354849)
62. Dake D (2011) The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. LINC Congress, Leipzig, Grmany
63. ML Linenberger AK Wittkowsky 2005 Thromboembolic complications of malignancy. Part 1: risks Oncology (Williston Park) 19 1077 1084 (Pubitemid 41725376)